Table 6 Linezolid Cmin of the first measurement (first Cmin) at 12, 24, 36, or 48 h after starting administration of fixed 600 mg every 12 h and ratio of first Cmin to mean Cmin under steady state in the RI group and non-RI group
From: Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients
Time after starting administration of fixed 600 mg every 12 h (h) | Linezolid Cmin of first measurement (first Cmin), mean ± SD (range) | Ratio of first Cmin to mean Cmin under steady state, median (IQR) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
RI group | n | Non-RI group | n | P-value | RI group | n | Non-RI group | n | P-value | |
12 | 8.9 ± 0.4 (8.6–9.4) | 3 | 6.2 ± 3.7 (0.2–14.0) | 17 | 0.090 | 52.0 (24.3–75.6) | 3 | 52.0 (26.4–80.7) | 17 | 0.96 |
24 | 12.3 ± 8.8 (2.9–24.3) | 7 | 8.3 ± 3.6 (4.8–14.2) | 5 | 0.75 | 81.8 (64.4–118.3) | 7 | 58.2 (27.3–64.4) | 5 | 0.051 |
36 | 18.8 ± 3.6 (16.2–21.3) | 2 | 9.6 ± 7.8 (0.5–23.3) | 7 | 0.19 | 67.6 (41.7–102.0) | 2 | 61.3 (45.1–77.5) | 7 | 0.88 |
48 | 25.3 ± 9.6 (15.8–36.1) | 4 | 8.7 ± 4.8 (1.4–14.7) | 8 | 0.0085 | 62.3 (45.8–79.1) | 4 | 79.1 (55.0–86.8) | 8 | 0.44 |
Total | 15.7 ± 9.5 (2.9–36.1) | 16 | 7.7 ± 4.9 (0.2–23.3) | 37 | 0.0019 | 58.9 (37.8–89.1) | 16 | 60.5 (38.7–79.9) | 37 | 0.71 |